Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet

A double-center, open-label, two-way crossover study was conducted in 24 healthy volunteers to assess the bioequivalence of a combined lamivudine/zidovudine tablet related to a reference and test drug products. The volunteers were randomly assigned to receive one lamivudine/zidovudine combination ta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Souza, Jacqueline de, Kano, Eunice K., Koono, Eunice E., Schramm, Simone G., Porta, Valentina, Storpiritis, Sílvia
Formato: Articulo
Lenguaje:Inglés
Publicado: 2009
Materias:
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/7779
http://www.latamjpharm.org/trabajos/28/3/LAJOP_28_3_1_16_V0B1X2XE46.pdf
Aporte de:
id I19-R120-10915-7779
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Farmacia
Farmacología
lamivudine; zidovudine; bioequivalencia
Farmacocinética
lamivudine; zidovudine; bioequivalence
spellingShingle Farmacia
Farmacología
lamivudine; zidovudine; bioequivalencia
Farmacocinética
lamivudine; zidovudine; bioequivalence
Souza, Jacqueline de
Kano, Eunice K.
Koono, Eunice E.
Schramm, Simone G.
Porta, Valentina
Storpiritis, Sílvia
Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
topic_facet Farmacia
Farmacología
lamivudine; zidovudine; bioequivalencia
Farmacocinética
lamivudine; zidovudine; bioequivalence
description A double-center, open-label, two-way crossover study was conducted in 24 healthy volunteers to assess the bioequivalence of a combined lamivudine/zidovudine tablet related to a reference and test drug products. The volunteers were randomly assigned to receive one lamivudine/zidovudine combination tablet of reference or test product with 7-days washout period between. Blood samples were collected up to 36 h post dose. Pharmacokinetic parameters were estimated. Drug products were bioequivalent if 90% confidence intervals for the ratio of least squares (CI 90%) means are under plasma concentration-time curve (AUC<sub>0-τ</sub> ) and absorption rate (C<sub>max</sub>) fell within 80 to 125% for log-transformed parameters. Test and reference products present data of AUC<sub>0-τ</sub> , C<sub>max</sub> referents to lamivudine and data of ASC∞ referents to zidovudine, in agreement of these limits. The result of C<sub>max</sub> (CI 90%) to zidovudine was: 116% (90- 141%), it has confirm that the zidovudine has high individual variability of absorption.
format Articulo
Articulo
author Souza, Jacqueline de
Kano, Eunice K.
Koono, Eunice E.
Schramm, Simone G.
Porta, Valentina
Storpiritis, Sílvia
author_facet Souza, Jacqueline de
Kano, Eunice K.
Koono, Eunice E.
Schramm, Simone G.
Porta, Valentina
Storpiritis, Sílvia
author_sort Souza, Jacqueline de
title Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
title_short Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
title_full Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
title_fullStr Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
title_full_unstemmed Bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
title_sort bioequivalence test applied to a new lamivudine/zidovudine combined formulation tablet
publishDate 2009
url http://sedici.unlp.edu.ar/handle/10915/7779
http://www.latamjpharm.org/trabajos/28/3/LAJOP_28_3_1_16_V0B1X2XE46.pdf
work_keys_str_mv AT souzajacquelinede bioequivalencetestappliedtoanewlamivudinezidovudinecombinedformulationtablet
AT kanoeunicek bioequivalencetestappliedtoanewlamivudinezidovudinecombinedformulationtablet
AT koonoeunicee bioequivalencetestappliedtoanewlamivudinezidovudinecombinedformulationtablet
AT schrammsimoneg bioequivalencetestappliedtoanewlamivudinezidovudinecombinedformulationtablet
AT portavalentina bioequivalencetestappliedtoanewlamivudinezidovudinecombinedformulationtablet
AT storpiritissilvia bioequivalencetestappliedtoanewlamivudinezidovudinecombinedformulationtablet
bdutipo_str Repositorios
_version_ 1764820485090050048